Plaque sealing by coronary angioplasty

B Meier

The concept of plaque sealing by coronary balloon angioplasty has been around for some time. It is based on two principles. First, a coronary stenosis subjected to balloon angioplasty will not progress to a total occlusion later on unless it occludes abruptly during or immediately after the intervention. Even if a restenosis occurs, the smooth inner lining of the intimal proliferation virtually precludes endothelial rupture and thrombosis. Second, preventing plaque rupture and occlusive thrombosis impacts on the occurrence of myocardial infarction and death. Normalising the blood flow in a significantly stenosed coronary segment only addresses symptoms such as angina pectoris and perhaps exertional dyspnoea. The uncontested benefit of balloon angioplasty, namely alleviation of angina, deals with a lifestyle problem (physical performance, elimination of medications) but not with the prognosis. Hence, restricting indications for coronary angioplasty to flow limiting lesions means barking up the wrong tree by ignoring what really counts—prevention of coronary occlusion and its devastating effects.

The plaque sealing principle has not been widely followed in spite of its theoretical appeal, mainly because of lack of documentation that balloon angioplasty indeed prevents subsequent myocardial infarction. For obvious reasons, such a strategy needs to be restricted to conspicuous and discrete narrowings in proximal segments of major coronary arteries. This may be a 60% 10 mm long stenosis in a proximal left anterior descending, dominant left circumflex, or large right coronary artery. Long lesions or lesions involving complex bifurcations may have a higher intervention risk than potential benefit over several subsequent years. Moreover, the principle cannot necessarily be extrapolated to coronary stenting with its small but significant bane of subacute thrombosis unknown to plain balloon angioplasty.

As outlined in the two previous reviews, the unstable plaque, the target of plaque sealing, exhibits a number of specific characteristics. The fibrous cap separating the plaque from the lumen is thin and eroded, at least in localised areas. It is lipid-rich with about 90% of macrophages being activated and half of them apoptotic. The intima contains only about 10% smooth muscle cells but many inflammatory cells. The collagen layers under the surface of the plaque are actively being destroyed by abundant matrix metalloproteinase, which again is stimulated by macrophages. Foam cells and activated angiotensin converting enzymes further destabilise the thin remaining protective layer.

It is exactly at these vulnerable zones where balloon angioplasty impacts first and most. It induces an immediate rupture of the thin fibrous cap. In contrast to spontaneous rupture this occurs under heparinisation and at a moment where coronary flow is optimised and observed. Assuming the risk of immediate thrombosis is only about 5% or 2% now that stents are available to remedy impending occlusions, the subsequent risk for later infarction originating at this preventively dilated site is minute if not absent, this appears to be a favourable prognosis compared with the annual risk of infarction of a mild coronary lesion assessed at about 2% per year by the CASS (coronary artery surgery study) registry. Admittedly, this risk was assessed without the benefit of some of the pharmaceutical plaque pacifiers already discussed in the preceding articles, such as statins, thienopyridines, or angiotensin converting enzyme inhibitors.

The mechanism of plaque sealing and restenosis is the same. Intimal proliferation provides a new, smooth, and elastic coat to the ruptured plaque. This new cap may significantly reduce the lumen, hence cause restenosis, but it is not subject to the risk of rupture and thrombosis as was the brittle cap before balloon angioplasty. Smooth muscle cells are a prominent part of the new intima. They produce plaque smoothening proteins. They also strengthen the fibrous cap and favourably regulate the synthesis of interstitial collagen.

CLINICAL EVIDENCE OF EFFICACY OF MECHANICAL PLAQUE SEALING

A Japanese study looked at 300 coronary sites angiographically at an average of seven years after balloon angioplasty. All these sites had been subjected to balloon angioplasty and found normally patent at a follow up angiogram six months after the intervention. Only two sites (0.7%) were suspected to have caused a myocardial infarction during the seven year observation period. All other sites (99.3%) were clearly identified as not being involved in the numerous infarctions that had occurred in the 249 patients since their initial angioplasty.

A retrospective analysis of over 3000 patients after successful balloon angioplasty proved that even the occurrence of restenosis did not increase mortality in the first six years of follow up. This strongly suggests that even overshooting intimal proliferation lacks the risk of infarction as infarctions always translate to increased mortality.

In a large retrospective analysis on about 4000 patients undergoing balloon angioplasty complemented by stenting in 61% for lesions of various degrees of severity, the one year event rates of death, myocardial infarction, or repeat revascularisation did not differ between lesions of less than 50% diameter stenosis, lesions of 50–99% diameter stenosis, or total occlusions. Mortality and infarction rates were too low to be analysed separately. Thus, a benefit of plaque sealing of non-significant lesions could not be derived, but there was no disadvantage either. The one year follow up may have been too short to bring out the potential of plaque sealing.

The DEFER trial was designed to prove that coronary angioplasty or stenting of a haemodynamically significant lesion is deleterious. About 200 patients with an angiographically identified lesion that had a normal fractional flow reserve (> 0.75) were randomised to undergo angioplasty (plaque sealing) with stent implantation in 46% or continued medical treatment. Event-free survival at 24 months did not differ between the two groups. Again the concept of plaque sealing was neither proved nor disproved, as the actively treated patients did not show an advantage at two years.
strategies already discussed. Any coronary lesion can produce mechanical means in addition to drugs and behavioural
mechanisms. The remaining 14% are caused by the lesions that were recently assessed as less than 50% and an additional 18% by 50–70% lesions. Ischaemic infarctions are caused by lesions that were recently assessed as haemodynamically significant but not to the extent of a severe stenosis. As there are usually many mild lesions to every severe lesion, it comes as no surprise that most infarctions are caused by mild lesions. A review of pertinent articles has shown that 68% of infarctions are caused by lesions that were recently assessed to be less than 50% and an additional 18% by 50–70% lesions. The remaining 14% are caused by the significant lesions that represent universally accepted targets for angioplasty. Hence, there is a potential to help prevent 84% of infarctions with mechanical means in addition to drugs and behavioural strategies already discussed. Any coronary lesion can produce a myocardial infarction at any time of the day when the message of a seminal article published 15 years ago was again applicable. It makes sense to use balloon dilatations in proximally situated short lesions that at least raise the suspicion of haemodynamic significance (for example, at least 50% of diameter obstruction). The procedure should be done ad hoc during the diagnostic study to remain as cost efficient as possible. To terminate the diagnostic study and send the patient for an exercise test or a nuclear study does not make sense based on the concept that it is not the haemodynamic significance but the potential to cause infarction that provides the indication for angioplasty. If one or more significant lesions are treated at the same time, plaque sealing of one or more additional non-significant lesions becomes even more attractive as little additional material will be required that would not have been used anyway. Stents should be used when necessary but not invariably. It can be estimated that about 3% of cases will show a menacing dissection that mandatorily needs to be stented. In an additional 30%, the result may look suboptimal and stents will be inserted preventively. As we are dealing with mild and short lesions in large vessels, good and durable balloon alone results can be anticipated in about 90% without stenting. The comparative stent trials dealing with significant lesions cannot be translated to non-significant lesions without a conversion rate. Drug eluting stents do not really influence this recommendation, as they have at least as high a subacute thrombosis risk as bare stents, and because restenosis in mild lesions is already rare with balloon dilatation alone (about 10%) or with a bare stent (about 5%).

PRELIMINARY ASSESSMENT OF VULNERABILITY OF THE PLAQUE

Many methods have been advanced to assess the vulnerability of coronary plaques. The most discussed ones are listed in table 1.18–21

None of these techniques have reached clinical application and few, if any, ever will. They are costly and flawed with some intrinsic complications. If a diagnostic angiogram shows a haemodynamically non-significant lesion meeting the requirements for plaque sealing enumerated above is complemented by one of the diagnostic studies in the table, there is scientific justification for it. However, there is little to gain. If the test proves the plaque to be unstable, the plaque sealing procedure will be performed anyway and the money spent on the diagnosis has been ill invested. If there is no evidence of vulnerability with one of the methods, perhaps another one will be used. If there is still no sign of vulnerability, angioplasty will be foregone for now. Nonetheless, their lesions were taken care of whereas in the other patients the lesions were still there as a kind of Damoclean swords with their small but relevant potential for infarction or death. Incidentally, at least one of the two study related cardiac deaths in the conservative group occurred from a spontaneous plaque rupture of a medically treated non-significant lesion (personal communication). In addition the stenting in half the patients may have wiped out some of the potential benefits of mechanical plaque sealing due to the well recognised risk of subacute stent thrombosis of about 1%.

In a way, this is already happening time and time again, albeit not under the heading of plaque sealing. It is of some concern that angioplasty of mild lesions seems to be gaining ground only after the introduction of drug eluting stents. Stents, and that includes drug eluting stents, should play a minor role in mild lesions. Notwithstanding, it emerges that they will be used in all these cases and even cited as the justification to treat non-significant stenoses—that is, perform plaque sealing.

CONCLUSIONS

In spite of lack of scientific proof, I should like to submit that plaque sealing by mechanical means is more important than plumbing in terms of prognosis of the patients, even though it can only be applied to a selection of stenoses and is far from being foolproof. A somewhat cynical statement by Spencer B King III, MD, on the occasion of a live angioplasty course in Atlanta, USA, on 29 May 2003 points in the same direction: “How to decide whether or not to dilate a mild lesion? If you want to dilate it, do IVUS (intravascular ultrasound); if you don’t, do the flow wire!”

In a way, this is already happening time and time again, albeit not under the heading of plaque sealing. It is of some concern that angioplasty of mild lesions seems to be gaining ground only after the introduction of drug eluting stents. The只要为患者提供预防性的措施。尽管如此，它们在所有这类患者中都将被使用，并且常常被纳入对非显著性斑块的治疗——即，进行斑块密封。

CONCLUSIONS

尽管缺乏科学证据，我仍然希望提交这项发表在杂志上的声明，即通过机械方法进行斑块密封比进行管道维修在患者中的治疗效果更佳。尽管如此，它只能应用于某些斑块的筛选，并且离实际应用还有一定距离。一种有些讽刺的声明来自Spencer B King III, MD，在他于亚特兰大举行的实时冠状动脉介入课程上，于2003年5月29日提出的同一方向：“如果想进行扩张，做IVUS（血管内超声）；如果不做，就做流量导丝！”

在某种程度上，这种情况已经在不断发生，尽管时间有所不同，并且没有被冠状动脉斑块密封的头衔。然而，它涉及的仅仅是药物涂层支架，所以它们在所有这类患者中都将被使用，并且常常被纳入对非显著性斑块的治疗——即，进行斑块密封。

CONCLUSIONS

尽管缺乏科学证据，我仍然希望提交这项发表在杂志上的声明，即通过机械方法进行斑块密封比进行管道维修在患者中的治疗效果更佳。尽管如此，它只能应用于某些斑块的筛选，并且离实际应用还有一定距离。一种有些讽刺的声明来自Spencer B King III, MD，在他于亚特兰大举行的实时冠状动脉介入课程上，于2003年5月29日提出的同一方向：“如果想进行扩张，做IVUS（血管内超声）；如果不做，就做流量导丝！”

在某种程度上，这种情况已经在不断发生，尽管时间有所不同，并且没有被冠状动脉斑块密封的头衔。然而，它涉及的仅仅是药物涂层支架，所以它们在所有这类患者中都将被使用，并且常常被纳入对非显著性斑块的治疗——即，进行斑块密封。
Correspondence to: Professor Bernhard Meier, Swiss Cardiovascular Center Bern, University Hospital, 3010 Bern, Switzerland; bernhard.meier@insel.ch

REFERENCES


IMAGES IN CARDIOLOGY

Cardiac papillary fibroelastoma of the mitral valve chordae

Papillary fibroelastoma of the mitral valve does not occur frequently, with fewer than 50 cases being reported in the literature. Therefore each case is interesting to report in order to improve the diagnosis and management of this uncommon tumour. We report an image of a fibroelastoma of the mitral valve chordae, without mitral insufficiency, discovered accidentally.

Papillary fibroelastoma was first described as gigantic Lambli’s excrescences. In typical cases papillary fibroelastoma resembles a sea anemone with multiple papillary fronds attached to the endocardium by a short pedicle. Primary tumours of the heart and pericardium are extremely rare, with an incidence between 0.0017–0.28% in reported or collected necropsy series. More than 70% of these tumours are benign, and only 8% are papillary fibroelastomas, mostly located on heart valves. Cardiac primary fibroelastoma (CPFPE) is by far the most common tumour arising from cardiac valves (about 70–80%). CPFPEs are small, avascular, benign tumours. The most frequent location is the valvar endocardium of the aortic valve (30%) and the mitral valve (20–25%). Only 10% are non-valvar. Because of their potential for cerebral and coronary embolism, even small papillary fibroelastomas should be excised, even in asymptomatic patients.
Cardiac papillary fibroelastoma of the mitral valve chordae

J P Remadi, A Degandt and Z Rakotoarivello

*Heart* 2004 90: 1397
doi: 10.1136/hrt.2003.032870

Updated information and services can be found at:
http://heart.bmj.com/content/90/12/1397

**Email alerting service**

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Notes**

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/